The FLT3^N701K mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinib

Affiliations

• ¹ Department of Medicine, Stanford University School of Medicine, Stanford, California, USA.
• ² Knight Cancer Institute, Oregon Health & Science University, Portland, Oregon, USA.
• ³ Division of Hematology & Medical Oncology, Department of Medicine, Oregon Health & Science University, Portland, Oregon, USA.
• ⁴ Division of Hematology and Oncology, Department of Medicine, University of California San Francisco, San Francisco, California, USA.
• ⁵ Division of Hematology and Oncology, Department of Pediatrics, University of California San Francisco, San Francisco, California, USA.
• ⁶ Helen Diller Family Comprehensive Cancer Center, University of California San Francisco, San Francisco, California, USA.
• ⁷ Division of Hematology and Oncology, Department of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
• ⁸ Department of Cell, Developmental & Cancer Biology, Oregon Health & Science University, Portland, Oregon, USA.